Literature DB >> 28656373

Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice.

Alan Dal Pra1, Cedric Panje2, Thomas Zilli3, Winfried Arnold4, Kathrin Brouwer5, Helena Garcia6, Markus Glatzer2, Silvia Gomez7, Fernanda Herrera8, Khanfir Kaouthar9, Alexandros Papachristofilou10, Gianfranco Pesce11, Christiane Reuter12, Hansjörg Vees13, Daniel Rudolf Zwahlen14, Daniel Engeler15, Paul Martin Putora2.   

Abstract

INTRODUCTION: Although salvage radiotherapy (SRT) for PSA recurrence after radical prostatectomy provides better oncological outcomes when delivered early, in the absence of detectable disease many patients are treated for macroscopic locally recurrent tumors. Due to limited data from prospective studies, we hypothesized an important variability in the SRT management of these patients. Our aim was to investigate current practice patterns of SRT for local macroscopic recurrence after radical prostatectomy.
MATERIAL AND METHODS: A total of 14 Swiss radiation oncology centers were asked to complete a survey on treatment specifications for macroscopic locally recurrent disease including information on pretherapeutic diagnostic procedures, dose prescription, radiation delivery techniques and androgen deprivation therapy (ADT). Treatment recommendations on ADT were analyzed using the objective consensus methodology.
RESULTS: The majority of centers recommended pretreatment magnetic resonance imaging (MRI) of the pelvis and choline positron emission tomography (PET). The median prescribed dose to the prostate bed was 66 Gy (range 65-72 Gy) with a boost to the macroscopic lesion used by 79% of the centers with a median total dose of 72 Gy (range 70-80 Gy). Intensity-modulated rotational techniques were used by all centers and daily cone beam computed tomography (CT) was recommended by 43%. The use of concomitant ADT for any macroscopic recurrence was recommended by 43% of the centers while the remaining centers recommended it only for high-risk disease, which was not consistently defined.
CONCLUSION: We observed a high variability of treatment paradigms when SRT is indicated for macroscopic local recurrences after prostatectomy. These data reflect the need for more standardized approaches and ultimately further research in this field.

Entities:  

Keywords:  Macroscopic recurrence; Postoperative radiotherapy; Prostate cancer; Radiotherapy; Salvage radiotherapy

Mesh:

Year:  2017        PMID: 28656373     DOI: 10.1007/s00066-017-1172-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  38 in total

1.  Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.

Authors:  A Dal Pra; F L Cury; L Souhami
Journal:  Curr Oncol       Date:  2010-10       Impact factor: 3.677

2.  Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.

Authors:  X Allen Li; Jian Z Wang; Paul A Jursinic; Colleen A Lawton; Dian Wang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-15       Impact factor: 7.038

3.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Authors:  William U Shipley; Wendy Seiferheld; Himanshu R Lukka; Pierre P Major; Niall M Heney; David J Grignon; Oliver Sartor; Maltibehn P Patel; Jean-Paul Bahary; Anthony L Zietman; Thomas M Pisansky; Kenneth L Zeitzer; Colleen A F Lawton; Felix Y Feng; Richard D Lovett; Alexander G Balogh; Luis Souhami; Seth A Rosenthal; Kevin J Kerlin; James J Dignam; Stephanie L Pugh; Howard M Sandler
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

Review 4.  What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation.

Authors:  Nicholas G Zaorsky; Joshua D Palmer; Mark D Hurwitz; Scott W Keith; Adam P Dicker; Robert B Den
Journal:  Radiother Oncol       Date:  2015-05-28       Impact factor: 6.280

5.  A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.

Authors:  Jacob G Scott; Anders Berglund; Michael J Schell; Ivaylo Mihaylov; William J Fulp; Binglin Yue; Eric Welsh; Jimmy J Caudell; Kamran Ahmed; Tobin S Strom; Eric Mellon; Puja Venkat; Peter Johnstone; John Foekens; Jae Lee; Eduardo Moros; William S Dalton; Steven A Eschrich; Howard McLeod; Louis B Harrison; Javier F Torres-Roca
Journal:  Lancet Oncol       Date:  2016-12-18       Impact factor: 41.316

6.  Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer.

Authors:  Jeff M Michalski; Colleen Lawton; Issam El Naqa; Mark Ritter; Elizabeth O'Meara; Michael J Seider; W Robert Lee; Seth A Rosenthal; Thomas Pisansky; Charles Catton; Richard K Valicenti; Anthony L Zietman; Walter R Bosch; Howard Sandler; Mark K Buyyounouski; Cynthia Ménard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-23       Impact factor: 7.038

7.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

8.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Authors:  Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

Review 9.  Rising prostate-specific antigen after primary prostate cancer therapy.

Authors:  John F Ward; Judd W Moul
Journal:  Nat Clin Pract Urol       Date:  2005-04

Review 10.  Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.

Authors:  Gaël Amzalag; Olivier Rager; Claire Tabouret-Viaud; Michael Wissmeyer; Electra Sfakianaki; Thomas de Perrot; Osman Ratib; Raymond Miralbell; Giampiero Giovacchini; Valentina Garibotto; Thomas Zilli
Journal:  Front Oncol       Date:  2016-03-31       Impact factor: 6.244

View more
  5 in total

1.  Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain.

Authors:  F Couñago; G Sancho; A Gómez-Iturriaga; I Henríquez
Journal:  Clin Transl Oncol       Date:  2018-07-10       Impact factor: 3.405

2.  Multiparametric magnetic resonance imaging-guided salvage radiotherapy in prostate cancer.

Authors:  Felipe Couñago; Ana Aurora Díaz Gavela; Gemma Sancho; Irene Ortiz; Francisco José Marcos; Manuel Recio; Julio Fernández; Raquel Cano; Mar Jiménez; Israel J Thuissard; David Sanz-Rosa; Juan Castro Nováis; Eduardo Pardo; Yolanda Molina; Hugo Pérez García; Elia Del Cerro
Journal:  Rep Pract Oncol Radiother       Date:  2019-08-08

3.  Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.

Authors:  Cedric Panje; Thomas Zilli; Alan Dal Pra; Winfried Arnold; Kathrin Brouwer; Helena I Garcia Schüler; Silvia Gomez; Fernanda Herrera; Kaouthar Khanfir; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Zwahlen; Paul Martin Putora
Journal:  Radiat Oncol       Date:  2019-10-16       Impact factor: 3.481

4.  Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy.

Authors:  Sung Uk Lee; Kwan Ho Cho; Jin Ho Kim; Young Seok Kim; Taek-Keun Nam; Jae-Sung Kim; Jaeho Cho; Seo Hee Choi; Su Jung Shim; Jin Hee Kim; Ah Ram Chang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era.

Authors:  Jörg Tamihardja; Leonie Zehner; Philipp E Hartrampf; Sinan Cirsi; Sonja Wegener; Andreas K Buck; Michael Flentje; Bülent Polat
Journal:  Cancers (Basel)       Date:  2022-10-10       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.